Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 2/20 | 0.33 |
| ▸ | JAK1 | P23458 | 7/20 | 0.32 |
| ▸ | PARP1 | P09874 | 6/20 | 0.32 |
| ▸ | JAK2 | O60674 | 5/20 | 0.31 |
| ▸ | TYK2 | P29597 | 3/20 | 0.31 |
| ▸ | IKBKB | O14920 | 1/20 | 0.31 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.31 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19658699 | 0.73 | GRM2 (0.44) | NUDT1JAK1LCK | |
| SCHEMBL2730240 | 0.73 | NUDT1 (0.62) | NUDT1JAK1PARP1JAK2EGLN2 | |
| SCHEMBL22439076 | 0.72 | KDM4E (0.43) | NUDT1PARP1 | |
| SCHEMBL22888415 | 0.72 | IRAK4 (0.43) | JAK1JAK2TYK2SYKJAK3 | |
| SCHEMBL19658700 | 0.70 | NUDT1 (0.38) | NUDT1JAK1PARP1JAK2TYK2 | |
| SCHEMBL28485655 | 0.69 | AHR (0.47) | NUDT1PARP1 | |
| SCHEMBL19658956 | 0.69 | PARP1 (0.39) | NUDT1JAK1PARP1JAK2 | |
| SCHEMBL19658973 | 0.69 | L3MBTL1 (0.36) | NUDT1PARP1JAK2 | |
| SCHEMBL19659253 | 0.69 | EGLN2 (0.50) | NUDT1JAK1PARP1JAK2TYK2 | |
| SCHEMBL19659614 | 0.66 | KDM4E (0.43) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3760625-A1 | BICYCLIC LACTAMS AS RECEPTOR-INTERACTING PROTEIN-1 (RIP1) KINASE INHIBITORS FOR TREATING E.G. INFLAMMATORY DISEASES | F. Hoffmann-La Roche AG (CH) | 2021-01-06 | — | — | EP | disclosed |